Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Nonmelanoma skin cancer, primarily comprising basal cell carcinoma and cutaneous squamous cell carcinoma, represents one of the most common malignancies worldwide and a growing public health concern. According to Mingyue Wang et al., 2024, estimates, nonmelanoma skin cancers were the fifth most common cancer globally, with approximately 1,234,533 new cases and around 69,416 deaths reported worldwide in that year. Its prevalence continues to rise, particularly among aging populations and regions with high ultraviolet exposure, contributing to a substantial healthcare burden despite relatively low mortality. The nonmelanoma skin cancer pipeline analysis by Expert Market Research highlights continued innovation across emerging therapies for nonmelanoma skin cancer aimed at improving long-term disease control.

  • Major companies involved in the nonmelanoma skin cancer pipeline analysis include Phio Pharmaceuticals Inc., Onchilles Pharma Inc., and others.

  • Leading drugs currently in the pipeline include Cemiplimab, AZD6750, RP1, and others.

  • The pipeline is driven by the rising incidence of advanced basal and squamous cell carcinomas, increasing adoption of immunotherapies such as cemiplimab, and innovations in early-stage nonmelanoma cancer treatments.

Report Coverage

The Nonmelanoma Skin Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into nonmelanoma skin cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nonmelanoma skin cancer. The nonmelanoma skin cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The nonmelanoma skin cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nonmelanoma skin cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nonmelanoma skin cancer.

Nonmelanoma Skin Cancer Pipeline Analysis by Drug Class

Read more about this report - Request a Free Sample

Nonmelanoma Skin Cancer Pipeline Outlook

Nonmelanoma skin cancer is a group of malignancies, primarily basal cell carcinoma and squamous cell carcinoma, arising from abnormal growth of skin cells due to prolonged ultraviolet radiation exposure. Genetic mutations, environmental factors, and immune suppression contribute to its development, driving advancements in the novel targeted therapies for skin cancer pipeline.

Nonmelanoma skin cancer treatment includes surgical excision, radiation therapy, and evolving options such as immunotherapy pipeline for nonmelanoma skin cancer and topical treatments in skin cancer pipeline, enhancing precision, efficacy, and patient outcomes. In October 2025, FDA approved cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adults with high-risk CSCC following surgery and radiotherapy, aimed at lowering the risk of disease recurrence. Emerging agents in trials seek enhanced efficacy with favorable safety profiles.

Nonmelanoma Skin Cancer Epidemiology

Nonmelanoma skin cancers, primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are among the most frequently diagnosed cancers worldwide. According to Mingyue Wang et al., 2024, there were an estimated 1.23 million new NMSC cases and about 69,000 deaths globally in that year, ranking NMSC fifth in overall cancer incidence. Incidence is highest in high-income regions such as Australasia, North America, and Europe, driven by ultraviolet exposure and aging populations, while rates in Asia and Africa remain lower. The nonmelanoma skin cancer burden continues to increase with demographic shifts and enhanced detection.

Nonmelanoma Skin Cancer – Pipeline Therapeutic Assessment

This section of the report covers the analysis of nonmelanoma skin cancer drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase 1)
  • Preclinical and Discovery Stage Products

By Drug Class

The nonmelanoma skin cancer pipeline analysis report covers 50+ drug analyses based on drug classes:

  • Small Molecules
  • Monoclonal Antibodies
  • Peptides
  • Polymers
  • Gene Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

  • Oral
  • Parenteral
  • Others

Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total nonmelanoma skin cancer clinical trials. The phase 1 covers 28%, phase 2 accounts for 44%, phase 3 covers 22% drugs, providing an in-depth analysis of each. The early phase 1 covers nearly 6% of investigational drugs for skin cancer treatment.

Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the nonmelanoma skin cancer pipeline analysis include monoclonal antibodies, small molecules, peptides, polymers, and gene therapies. The nonmelanoma skin cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nonmelanoma skin cancer. For instance, in December 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) for adults with advanced cutaneous squamous cell carcinoma that is locally advanced or metastatic and not suitable for curative surgery or radiotherapy.

Nonmelanoma Skin Cancer Clinical Trials – Key Players

The EMR report for the nonmelanoma skin cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed nonmelanoma skin cancer therapeutic assessment, analysing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in nonmelanoma skin cancer clinical trials:

  • Phio Pharmaceuticals Inc.
  • Onchilles Pharma Inc.
  • AstraZeneca
  • KaliVir Immunotherapeutics
  • Regeneron Pharmaceuticals
  • Stamford Pharmaceuticals, Inc.
  • Sirnaomics
  • AiViva BioPharma, Inc.
  • Feldan Therapeutics
  • Verrica Pharmaceuticals Inc.

Nonmelanoma Skin Cancer – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nonmelanoma skin cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nonmelanoma skin cancer drug candidates.

Drug: Cemiplimab

Cemiplimab (LIBTAYO) is being evaluated in a Phase 3 C-POST trial sponsored by Regeneron Pharmaceuticals in collaboration with Sanofi. The study examines its efficacy in preventing recurrence of high-risk cutaneous squamous cell carcinoma following surgery and radiation. Cemiplimab is a monoclonal antibody targeting the PD-1 receptor, enhancing immune-mediated tumor cell destruction, and is administered intravenously. The trial is demonstrating improved disease-free survival compared to placebo, with ongoing follow-up expected to continue through approximately 2030.

Drug: AZD6750

AZD6750 is a novel CD8‑guided interleukin‑2 (IL‑2) agent being evaluated for safety, pharmacokinetics and efficacy in advanced or metastatic solid tumors, including cutaneous squamous cell carcinoma (a form of nonmelanoma skin cancer). It may be administered alone or with other anticancer agents to stimulate immune‑mediated tumor control. AstraZeneca, a global biopharmaceutical leader in oncology, is conducting this Phase 1/2 clinical study as part of its broad immuno‑oncology pipeline. The study is expected to be completed by February 2029.

Drug: RP1

RP1 (vusolimogene oderparepvec) is being developed by Replimune Inc. as an oncolytic immunotherapy for nonmelanoma skin cancer. The Phase 2 IGNYTE study is evaluating safety and estimating efficacy of RP1, administered via intratumoral injection, both as monotherapy and in combination with nivolumab. The drug is engineered from a modified herpes simplex virus expressing GM-CSF and a fusogenic protein to enhance tumor cell lysis and systemic immune activation. The study is expected to be be completed by December 2028.

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Key Questions Answered in the Nonmelanoma Skin Cancer Pipeline Insight Report

  • Which companies/institutions are leading the nonmelanoma skin cancer drug development?
  • Which company is leading the nonmelanoma skin cancer pipeline development activities?
  • What is the current nonmelanoma skin cancer commercial assessment?
  • What are the opportunities and challenges present in the nonmelanoma skin cancer pipeline landscape?
  • What is the efficacy and safety profile of nonmelanoma skin cancer pipeline drugs?
  • Which company is conducting major trials for nonmelanoma skin cancer drugs?
  • Which companies/institutions are involved in nonmelanoma skin cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in nonmelanoma skin cancer?

Reasons To Buy This Report

The Nonmelanoma Skin Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for nonmelanoma skin cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into nonmelanoma skin cancer collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Nonmelanoma Skin Cancer Epidemiology Forecast

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Monoclonal Antibodies
  • Small Molecules
  • Peptides
  • Polymers
  • Gene Therapies

Leading Sponsors Covered

  • Phio Pharmaceuticals Inc.
  • Onchilles Pharma Inc.
  • AstraZeneca
  • KaliVir Immunotherapeutics
  • Regeneron Pharmaceuticals
  • Stamford Pharmaceuticals, Inc.
  • Sirnaomics
  • AiViva BioPharma, Inc.
  • Feldan Therapeutics
  • Verrica Pharmaceuticals Inc.

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us